← Back to Clinical Trials
Recruiting NCT07140757

NCT07140757 Radiofrequency Ablation for Management of Benign/Indeterminate Thyroid Nodules and Low Risk Papillary Thyroid Cancers

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07140757
Status Recruiting
Phase
Sponsor M.D. Anderson Cancer Center
Condition Low Risk
Study Type OBSERVATIONAL
Enrollment 50 participants
Start Date 2025-08-18
Primary Completion 2028-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Questionnaire

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 50 participants in total. It began in 2025-08-18 with a primary completion date of 2028-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

To track the outcomes of patients who have been treated with RFA and its long-term effectiveness, and to learn more about the quality of life of patients who have received RFA in this study.

Eligibility Criteria

Eligibility Criteria 1. Participants scheduled to undergo ultrasound-guided RFA for the following conditions: benign thyroid nodules, indeterminate thyroid nodules, low-risk DTC, and recurrent PTC 2. Participant is over 18 years and is either not a surgical candidate or has declined surgery. 3. Capable and willing to provide written informed consent 4. Participant has one of the following diagnoses: * Biopsy-proven benign thyroid nodules causing compressive and/or cosmetic symptoms who are requesting treatment, * Biopsy-proven indeterminate nodules (AUS or follicular neoplasm) * Papillary thyroid carcinoma (PTC) without metastasis * Locally recurrent thyroid cancer (\< 2 cm). Exclusion Criteria 1. Participants meeting any of the following criteria will be excluded: 2. Participants considered unsuitable for RFA by the treating physician

Contact & Investigator

Central Contact

Victoria E Banuchi, MD

✉ vebanuchi@mdanderson.org

📞 346-217-8668

Principal Investigator

Victoria E Banuchi, MD

STUDY DIRECTOR

M.D. Anderson Cancer Center

Frequently Asked Questions

Who can join the NCT07140757 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Low Risk. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07140757 currently recruiting?

Yes, NCT07140757 is actively recruiting participants. Contact the research team at vebanuchi@mdanderson.org for enrollment information.

Where is the NCT07140757 trial being conducted?

This trial is being conducted at Houston, United States.

Who is sponsoring the NCT07140757 clinical trial?

NCT07140757 is sponsored by M.D. Anderson Cancer Center. The principal investigator is Victoria E Banuchi, MD at M.D. Anderson Cancer Center. The trial plans to enroll 50 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology